Especially for HCC, increased serum VEGF expression is a poor prognostic biomarker in patients undergoing locoregional therapies such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE) [31,32] and hepatic resection [36]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.